⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278419 | 0.80 | — | — | |
| SCHEMBL16019411 | 0.80 | — | — | |
| SCHEMBL14361747 | 0.75 | — | — | |
| SCHEMBL570563 | 0.74 | — | — | |
| SCHEMBL7288781 | 0.63 | — | — | |
| SCHEMBL10343777 | 0.61 | — | — | |
| SCHEMBL13679406 | 0.61 | — | — | |
| SCHEMBL20686209 | 0.60 | CHRM1 (0.30) | — | |
| SCHEMBL15458668 | 0.59 | — | — | |
| SCHEMBL19057052 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220062296-A1 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20210253588-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2021-08-19 | — | — | US | disclosed |
| US-11083196-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-08-10 | — | — | US | disclosed |
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2021-01-14 | — | — | US | disclosed |
| US-10815242-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-9051546-B2 | Mutant hydroxyphenylpyruvate dioxygenase polypeptides and methods of use | SYNGENTA PARTICIPATIONS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-9051545-B2 | Mutant hydroxyphenylpyruvate dioxygenase polypeptides and methods of use | SYNGENTA PARTICIPATIONS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-20140323300-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140053295-A1 | MUTANT HYDROXYPHENYLPYRUVATE DIOXYGENASE POLYPEPTIDES AND METHODS OF USE | SYNGENTA CROP PROTECTION AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-7265127-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7253181-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-08-07 | — | — | US | disclosed |